{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-144470","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2024-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.337821+00:00","generated_at":"2026-06-01T09:49:35.948522+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Dyne Therapeutics prices $325.5M public offering of 10.5M shares at $31.00 per share","bullets":["Gross proceeds of $325.5M; net proceeds estimated at $305.4M ($351.4M if underwriters' option is fully exercised).","Underwriters include Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities; closing expected May 24, 2024.","Company granted 30-day option for underwriters to purchase an additional 1.575M shares at the same price.","Net proceeds plus existing cash expected to fund operations at least into the second half of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-144470","json":"https://secwatch.observer/filing/0001193125-24-144470.json","markdown":"https://secwatch.observer/filing/0001193125-24-144470.md","text":"https://secwatch.observer/filing/0001193125-24-144470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312524144470/0001193125-24-144470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312524144470/d812513d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:49:35.948522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}